Effectiveness and Safety of Fecal Microbiota Transplantation for Clostridioides Difficile Infection: Results From a 5344-Patient Cohort Study
Studies of the microbes living on and in our bodies are conducted mainly in a few rich countries, squandering opportunities to improve the health of people globally.
As Microbiome Science Forges Ahead, Will Some Be Left Behind?
The FDA’s approval of the first fecal microbiota treatment was a watershed moment — and also a wakeup call.
Boosting microbiome science worldwide could save millions of children’s lives
Boosting microbiome science worldwide could save millions of children’s lives.Studies of the microbes living on and in our bodies are conducted mainly in a few rich countries, squandering opportunities to improve the health of people globally.
AGA calls on FDA to Retain Access to Conventional FMT
In addition to the new FDA-approved therapies, we still need access to conventional fecal microbiota transplantation for complicated and vulnerable patients with C. diff infection.
Fecal microbiota transplantation for refractory immune-checkpoint-inhibitor colitis.
Strategies to restore or prevent microbiome injury—with a particular focus on salvage FMT after antibiotic injury—in the context of immunotherapy toxicities is explored, with a call for additional studies.
FMT Update & Future Directions
I am writing to share an important and transformative update about OpenBiome.
In light of the FDA’s recent decision to end enforcement discretion, we have had to make some difficult decisions—most notably, scaling back our exceptional team and ceasing the distribution of investigational Fecal Microbiota Transplants (FMT). The outcome, although unavoidable, deeply affects us all as we fully recognize the critical role this treatment has played for clinicians and the patients you care for, particularly those battling severe and fulminant Clostridioides difficile (C. diff) infections. Rest assured, however, that while it may take time, we are actively exploring new avenues to ensure patients can access this life-changing therapy.
Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent Clostridioides difficile Infection
The first prospective study that examines the efficacy of FMT among patients with IBD and CDI is explored.
Donor Screening for Fecal Microbiota Transplantation
Despite similarities in screening programs for safe Fecal Microbiota Treatments for recurrent c. Diff infections, characterizing the reasons for exclusion and reporting on the eligibility rates are studied.
Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Children
Findings from a large multi-center retrospective cohort, found FMT is effective and safe for the treatment of CDI in children and young adults.